ReviewDiabetes & metabolism journal2020
Comprehensive Review of Current and Upcoming Anti-Obesity Drugs.
Review in Diabetes & metabolism journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 4 syntheses or guidelines pooled it, 142 citations in OpenAlex.
- Hyperphagia in rare melanocortin-4 receptor pathway diseases: therapeutic options and assessing treatment response.Reviews in endocrine & metabolic disorders · 2025Pooled it
- Pharmacological and psychosocial interventions for night eating syndrome in adults.Frontiers in psychiatry · 2025Pooled it
- Surgery is associated with better long-term outcomes than pharmacological treatment for obesity: a systematic review and meta-analysis.Scientific reports · 2024Pooled it
- Striatal dopamine D2-like receptors availability in obesity and its modulation by bariatric surgery: a systematic review and meta-analysis.Scientific reports · 2023Pooled it
- Trial
- Trial
- Nanomaterial-driven modulation of lipid metabolism: Novel strategies toward precision obesity treatment.Bioactive materials · 2026Review
- Lipid-lowering activity of mulberry seed unsaturated fatty acids: integrating network pharmacology and experimental validation.Functional & integrative genomics · 2026Article
- Complement 3a Receptor mediates high fat diet induced hypothalamic accumulation of lipid associated microglia to regulate neuroinflammation and obesity.bioRxiv : the preprint server for biology · 2026Article
- Problems associated with the ATC system of drug classification.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Obesity medications and acquired hypothalamic obesity in adults: A two-case experience.Obesity pillars · 2026Article
- The Effects of Exercise Combined with Pharmacotherapy on Body Composition and Metabolic Parameters in Overweight/Obese Adults: A Meta-Analysis and Network Pharmacology Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Review
- The Impact of Bariatric Surgery on the Development and Progression of Dermatologic Diseases: A Narrative Review.Dermatology and therapy · 2026Review
- How diet therapy affects obesity-associated depressive symptoms: from mechanism to therapeutics.Frontiers in neuroscience · 2026Review
- Management of Acquired Hypothalamic Dysfunction and the Hypothalamic Syndrome; It Is More Than Obesity.Endocrine reviews · 2025Review
- Postbiotics fromNutrients · 2025Article
- Article
- Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review.World journal of gastroenterology · 2025Review
- The Gut Microbiome in Human Obesity: A Comprehensive Review.Biomedicines · 2025Review
- Curcumin alleviates visceral adiposity via inhibiting GIP release from hypoxic intestinal damage in MASH rats.NPJ science of food · 2025Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is among the leading causes of morbidity and mortality worldwide and its prevalence continues to increase globally. Because obesity is a chronic, complex, and heterogeneous disease influenced by genetic, developmental, biological, and environmental factors, it is necessary to approach obesity with an integrated and comprehensive treatment strategy. As it is difficult to achieve and sustain successful long-term weight loss in most patients with obesity through lifestyle modifications (e.g., diet, exercise, and behavioral therapy), pharmacological approaches to the treatment of obesity should be considered as an adjunct therapy. Currently, four drugs (orlistat, naltrexone extended-release [ER]/bupropion ER, phentermine/topiramate controlled-release, and liraglutide) can be used long-term (>12 weeks) to promote weight loss by suppressing appetite or decreasing fat absorption. Pharmacotherapy for obesity should be conducted according to a proper assessment of the clinical evidence and customized to individual patients considering the characteristics of each drug and comorbidities associated with obesity. In this review, we discuss the mechanisms of action, efficacy, and safety of these available long-term anti-obesity drugs and introduce other potential agents under investigation. Furthermore, we discuss the need for research on personalized obesity medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.